448 related articles for article (PubMed ID: 33072111)
1. Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment.
Ouyang J; Isnard S; Lin J; Fombuena B; Peng X; Routy JP; Chen Y
Front Immunol; 2020; 11():570063. PubMed ID: 33072111
[TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
Ranganathan S; Iyer RN
Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
[TBL] [Abstract][Full Text] [Related]
3. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
4. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
5. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.
Halstead SB; Akkina R
Front Immunol; 2020; 11():1196. PubMed ID: 32574267
[No Abstract] [Full Text] [Related]
7. Convalescent Plasma: Promise for COVID-19 Pandemic.
Sheikh S; Baig MA
J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
[No Abstract] [Full Text] [Related]
8. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
Subbarao K; Mordant F; Rudraraju R
Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
[TBL] [Abstract][Full Text] [Related]
9. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
Garraud O
Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
[No Abstract] [Full Text] [Related]
10. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
Morabito CJ; Gangadharan B
Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
[No Abstract] [Full Text] [Related]
11. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
12. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
Xi Y
Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
[No Abstract] [Full Text] [Related]
13. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
14. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
[TBL] [Abstract][Full Text] [Related]
15. Convalescent serum lines up as first-choice treatment for coronavirus.
Sheridan C
Nat Biotechnol; 2020 Jun; 38(6):655-658. PubMed ID: 32358594
[No Abstract] [Full Text] [Related]
16. Challenges of Convalescent Plasma Therapy on COVID-19.
Zhao Q; He Y
J Clin Virol; 2020 Jun; 127():104358. PubMed ID: 32305026
[No Abstract] [Full Text] [Related]
17. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
Rasheed AM; Fatak DF; Hashim HA; Maulood MF; Kabah KK; Almusawi YA; Abdulamir AS
Infez Med; 2020 Sep; 28(3):357-366. PubMed ID: 32920571
[TBL] [Abstract][Full Text] [Related]
18. Deployment of convalescent plasma for the prevention and treatment of COVID-19.
Bloch EM; Shoham S; Casadevall A; Sachais BS; Shaz B; Winters JL; van Buskirk C; Grossman BJ; Joyner M; Henderson JP; Pekosz A; Lau B; Wesolowski A; Katz L; Shan H; Auwaerter PG; Thomas D; Sullivan DJ; Paneth N; Gehrie E; Spitalnik S; Hod EA; Pollack L; Nicholson WT; Pirofski LA; Bailey JA; Tobian AA
J Clin Invest; 2020 Jun; 130(6):2757-2765. PubMed ID: 32254064
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.
Zhou G; Zhao Q
Int J Biol Sci; 2020; 16(10):1718-1723. PubMed ID: 32226289
[TBL] [Abstract][Full Text] [Related]
20. The resurgence of convalescent plasma therapy.
The Lancet Haematology
Lancet Haematol; 2020 May; 7(5):e353. PubMed ID: 32359447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
